BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other equities analysts also recently issued reports about the company. Citigroup raised their price objective on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Hold” and an average price target of $15.00.

BioAge Labs Trading Up 10.6%

Shares of BioAge Labs stock opened at $11.61 on Friday. The company has a market capitalization of $416.22 million, a PE ratio of -7.64 and a beta of 1.74. BioAge Labs has a twelve month low of $2.88 and a twelve month high of $20.37. The business has a fifty day simple moving average of $7.34.

BioAge Labs (NASDAQ:BIOA) last announced its earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.11. The company had revenue of $2.05 million for the quarter.

Insider Activity

In related news, insider Paul D. Rubin sold 68,897 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $10.19, for a total transaction of $702,060.43. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 20.82% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BioAge Labs

Hedge funds have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. bought a new position in shares of BioAge Labs during the 2nd quarter worth approximately $206,000. Public Employees Retirement System of Ohio bought a new stake in shares of BioAge Labs in the 2nd quarter valued at $57,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of BioAge Labs in the 2nd quarter valued at $27,000. Stonepine Capital Management LLC lifted its position in shares of BioAge Labs by 202.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after acquiring an additional 101,085 shares during the period. Finally, Occudo Quantitative Strategies LP bought a new position in BioAge Labs during the third quarter worth $113,000.

BioAge Labs Company Profile

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.